First Header Logo Second Header Logo

Connection

Steven Feldman to Psoriasis

Back to Details
This is a "connection" page, showing publications Steven Feldman has written about Psoriasis.
Steven Feldman
Connection Strength
80.125
Psoriasis
  1. Purvis CG, Emmerich VK, Feldman SR. Tildrakizumab: interpreting the data. Br J Dermatol. 2021 08; 185(2):242-243.
    View in: PubMed
    Score: 0.520
  2. Huang WW, Feldman SR. The next quantum leap forward? Bimekizumab for psoriasis. Lancet. 2021 02 06; 397(10273):446-448.
    View in: PubMed
    Score: 0.509
  3. Bell KA, Balogh EA, Feldman SR. An update on the impact of depression on the treatment of psoriasis. Expert Opin Pharmacother. 2021 Apr; 22(6):695-703.
    View in: PubMed
    Score: 0.501
  4. Svoboda SA, Ghamrawi RI, Owusu DA, Feldman SR. Treatment Goals in Psoriasis: Which Outcomes Matter Most? Am J Clin Dermatol. 2020 Aug; 21(4):505-511.
    View in: PubMed
    Score: 0.491
  5. Bray JK, Feldman SR. The ethical implications of utilizing advertising techniques to increase biologic treatment willingness in patients with psoriasis. Dermatol Online J. 2020 Jul 15; 26(7).
    View in: PubMed
    Score: 0.490
  6. Balogh EA, Bashyam AM, Ghamrawi RI, Feldman SR. Emerging systemic drugs in the treatment of plaque psoriasis. Expert Opin Emerg Drugs. 2020 06; 25(2):89-100.
    View in: PubMed
    Score: 0.480
  7. Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID-19 pandemic. J Dermatolog Treat. 2020 06; 31(4):317-318.
    View in: PubMed
    Score: 0.479
  8. Ramachandran V, Bertus B, Bashyam AM, Feldman SR. Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials. Ann Pharmacother. 2020 09; 54(9):872-878.
    View in: PubMed
    Score: 0.477
  9. Wilson BN, Balogh EA, Feldman SR. Medications in dermatology are safer and more efficient than they used to be. Expert Opin Drug Saf. 2020 Apr; 19(4):359-360.
    View in: PubMed
    Score: 0.476
  10. Haidari W, Pona A, Feldman SR. Management of Residual Psoriasis in Patients on Biologic Treatment J Drugs Dermatol. 2020 Feb 02; 19(2):188-194.
    View in: PubMed
    Score: 0.475
  11. Okwundu N, Cardwell LA, Cline AE, Richardson IM, Feldman SR. Adherence to topical treatment can improve treatment-resistant moderate psoriasis. Cutis. 2020 Feb; 105(2):89-91;E2;E3.
    View in: PubMed
    Score: 0.474
  12. Feldman SR. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 2020 01; 82(1):256-257.
    View in: PubMed
    Score: 0.472
  13. Feldman SR, Zhang J, Martinez DJ, Lopez-Gonzalez L, Marchlewicz EH, Shrady G, Mendelsohn AM, Zhao Y. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status. J Dermatolog Treat. 2021 Mar; 32(2):203-211.
    View in: PubMed
    Score: 0.470
  14. Bray JK, Cline A, Masicampo EJ, Kammrath L, Feldman SR. Comparing psoriasis advertisement methods with patient willingness to initiate treatment. J Dermatolog Treat. 2020 Sep; 31(6):626-630.
    View in: PubMed
    Score: 0.467
  15. Bray JK, Cline A, Feldman SR. Assessing perceived adverse effects of biologic medications for patients with psoriasis. J Am Acad Dermatol. 2020 03; 82(3):766-768.
    View in: PubMed
    Score: 0.467
  16. Li W, Ghamrawi R, Haidari W, Feldman SR. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis. Ann Pharmacother. 2020 04; 54(4):380-387.
    View in: PubMed
    Score: 0.466
  17. Felix K, Unrue E, Inyang M, Cardwell LA, Oussedik E, Richardson I, Feldman SR. Patients preferences for different corticosteroid vehicles are highly variable. J Dermatolog Treat. 2020 Mar; 31(2):147-151.
    View in: PubMed
    Score: 0.464
  18. Habet KA, Kolli SS, Pona A, Feldman SR. A review of topical corticosteroid sprays for the treatment of inflammatory dermatoses. Dermatol Online J. 2019 Aug 15; 25(8).
    View in: PubMed
    Score: 0.459
  19. Hall SL, Haidari W, Feldman SR. Resolution of Guttate Psoriasis Plaques After One-time Administration of Guselkumab J Drugs Dermatol. 2019 Aug 01; 18(8):822-823.
    View in: PubMed
    Score: 0.458
  20. Kolli SS, Huang WW, Feldman SR. Publication productivity of authors of psoriasis clinical practice guidelines with and without ties to industry. J Am Acad Dermatol. 2019 12; 81(6):1432-1433.
    View in: PubMed
    Score: 0.454
  21. Okwundu N, Cardwell L, Cline A, Richardson I, Feldman SR. Is topical treatment effective for psoriasis in patients who failed topical treatment? J Dermatolog Treat. 2021 Feb; 32(1):41-44.
    View in: PubMed
    Score: 0.453
  22. Kolli SS, Kepley AL, Cline A, Feldman SR. A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data. Expert Opin Drug Saf. 2019 06; 18(6):523-536.
    View in: PubMed
    Score: 0.451
  23. Wechter T, Seger EW, Cline A, Feldman SR. Can We Tell Patients That IL-23 and TNF-a Inhibition Are "Natural" Ways to Treat Psoriasis? J Cutan Med Surg. 2019 May/Jun; 23(3):337-338.
    View in: PubMed
    Score: 0.450
  24. Cline A, Unrue EL, Collins A, Feldman SR. Adherence to a novel home phototherapy system with integrated features. Dermatol Online J. 2019 Mar 15; 25(3).
    View in: PubMed
    Score: 0.446
  25. Pona A, Haidari W, Kolli SS, Feldman SR. Diet and psoriasis. Dermatol Online J. 2019 Feb 15; 25(2).
    View in: PubMed
    Score: 0.444
  26. Unrue EL, Cline A, Collins A, Nguyen VH, Pelle MT, Blake P, Feldman SR. A novel ultraviolet B home phototherapy system: Efficacy, tolerability, adherence, and satisfaction. Dermatol Online J. 2019 02 15; 25(2).
    View in: PubMed
    Score: 0.444
  27. Feldman SR, Regnier SA, Chirilov A, Hey F, Gilloteau I, Cella D. Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States. J Am Acad Dermatol. 2019 Jun; 80(6):1650-1657.
    View in: PubMed
    Score: 0.442
  28. Lewis DJ, Chan WH, Hinojosa T, Hsu S, Feldman SR. Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: A review. Clin Dermatol. 2019 Mar - Apr; 37(2):160-166.
    View in: PubMed
    Score: 0.441
  29. Heath MS, Kolli SS, Dowling JR, Cline A, Feldman SR. Pharmacotherapeutic strategies for standard treatment-resistant psoriasis. Expert Opin Pharmacother. 2019 03; 20(4):443-454.
    View in: PubMed
    Score: 0.440
  30. Wu JJ, Lu M, Veverka KA, Smulders M, Papademetriou E, Yu J, Feldman SR. The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment. J Dermatolog Treat. 2019 Aug; 30(5):446-453.
    View in: PubMed
    Score: 0.439
  31. Hogue L, Cardwell LA, Roach C, Felix KH, Oussedik E, Richardson I, Feldman SR. Psoriasis and Atopic Dermatitis "Resistant" to Topical Treatment Responds Rapidly to Topical Desoximetasone Spray. J Cutan Med Surg. 2019 Mar/Apr; 23(2):157-163.
    View in: PubMed
    Score: 0.439
  32. Stiff KM, Glines KR, Porter CL, Cline A, Feldman SR. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. Expert Rev Clin Pharmacol. 2018 Dec; 11(12):1209-1218.
    View in: PubMed
    Score: 0.438
  33. Feldman SR, Srivastava B, Abell J, Hoops T, Fakharzadeh S, Chakravarty S, Muser E, Dungee D, Quinn S, Leone-Perkins M, Kappelman M. Gastrointestinal Signs and Symptoms Related to Inflammatory Bowel Disease in Patients With Moderate-to-Severe Psoriasis J Drugs Dermatol. 2018 12 01; 17(12):1298-1308.
    View in: PubMed
    Score: 0.438
  34. Bartos G, Cline A, Beroukhim K, Burrall BA, Feldman SR. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. Dermatol Online J. 2018 Nov 15; 24(11).
    View in: PubMed
    Score: 0.436
  35. Feldman SR, Pelletier CL, Wilson KL, Mehta RK, Brouillette MA, Smith D, Bonafede MM. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics. J Comp Eff Res. 2019 01; 8(1):45-54.
    View in: PubMed
    Score: 0.435
  36. Kolli SS, Amin SD, Pona A, Cline A, Feldman SR. Psychosocial impact of psoriasis: a review for dermatology residents. Cutis. 2018 Nov; 102(5S):21-25.
    View in: PubMed
    Score: 0.435
  37. Kolli SS, Gabros SD, Pona A, Cline A, Feldman SR. Tildrakizumab: A Review of Phase II and III Clinical Trials. Ann Pharmacother. 2019 04; 53(4):413-418.
    View in: PubMed
    Score: 0.434
  38. Feldman SR, Hur P, Zhao Y, Tian H, Wei Z, Wang X, Herrera V. Incidence rates of comorbidities among patients with psoriasis in the United States. Dermatol Online J. 2018 Oct 15; 24(10).
    View in: PubMed
    Score: 0.434
  39. Kazemi A, Cline A, Cardwell LA, Feldman SR. Psoriasis therapy and aortic inflammation - translating statistical to clinical significance. Dermatol Online J. 2018 Sep 15; 24(9).
    View in: PubMed
    Score: 0.431
  40. Feaster B, Cline A, Feldman SR. Secukinumab for psoriasis in a patient with hepatitis B. Dermatol Online J. 2018 Sep 15; 24(9).
    View in: PubMed
    Score: 0.431
  41. Aleshaki JS, Cardwell LA, Muse ME, Feldman SR. Adherence and resource use among psoriasis patients treated with biologics. Expert Rev Pharmacoecon Outcomes Res. 2018 12; 18(6):609-617.
    View in: PubMed
    Score: 0.431
  42. Heath MS, Sahni DR, Curry ZA, Feldman SR. Pharmacokinetics of tazarotene and acitretin in psoriasis. Expert Opin Drug Metab Toxicol. 2018 Sep; 14(9):919-927.
    View in: PubMed
    Score: 0.430
  43. Cline A, Feldman SR. Risankizumab for psoriasis. Lancet. 2018 08 25; 392(10148):616-617.
    View in: PubMed
    Score: 0.428
  44. Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study. J Manag Care Spec Pharm. 2018 Jul; 24(7):617-622.
    View in: PubMed
    Score: 0.425
  45. Feldman SR, Wu JJ, Rastogi S, Menges B, Lingohr-Smith M, Lin J. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. J Med Econ. 2018 May; 21(5):537-541.
    View in: PubMed
    Score: 0.413
  46. Seale L, Cardwell LA, Feldman SR. Adherence to biologics in patients with psoriasis. Expert Rev Clin Immunol. 2018 02; 14(2):155-161.
    View in: PubMed
    Score: 0.412
  47. Arnold DL, Feldman SR. Comment on "Serious infections among a large cohort of subjects with systemically treated psoriasis". J Am Acad Dermatol. 2018 05; 78(5):e113-e114.
    View in: PubMed
    Score: 0.411
  48. Feldman SR, Foster SA, Zhu B, Burge R, Al Sawah S, Goldblum OM. Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis. J Drugs Dermatol. 2017 12 01; 16(12):1246-1252.
    View in: PubMed
    Score: 0.408
  49. Cline A, Cardwell LA, Feldman SR. Advances in treating psoriasis in the elderly with small molecule inhibitors. Expert Opin Pharmacother. 2017 Dec; 18(18):1965-1973.
    View in: PubMed
    Score: 0.408
  50. Howell ST, Cardwell LA, Feldman SR. Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials. Ann Pharmacother. 2018 04; 52(4):380-387.
    View in: PubMed
    Score: 0.407
  51. Patel N, Nadkarni A, Cardwell LA, Vera N, Frey C, Patel N, Feldman SR. Psoriasis, Depression, and Inflammatory Overlap: A Review. Am J Clin Dermatol. 2017 Oct; 18(5):613-620.
    View in: PubMed
    Score: 0.404
  52. Oussedik E, Patel NU, Cash DR, Gupta AS, Feldman SR. Severe and acute complications of biologics in psoriasis. G Ital Dermatol Venereol. 2017 Dec; 152(6):586-596.
    View in: PubMed
    Score: 0.402
  53. Oussedik E, Cardwell LA, Patel NU, Onikoyi O, Feldman SR. An Anchoring-Based Intervention to Increase Patient Willingness to Use Injectable Medication in Psoriasis. JAMA Dermatol. 2017 09 01; 153(9):932-934.
    View in: PubMed
    Score: 0.401
  54. Smith JA, Wehausen B, Richardson I, Zhao Y, Li Y, Herrera V, Feldman SR. Treatment Changes in Patients With Moderate to Severe Psoriasis: A Retrospective Chart Review. J Cutan Med Surg. 2018 Jan/Feb; 22(1):25-30.
    View in: PubMed
    Score: 0.399
  55. Feldman SR, Green L, Kimball AB, Siu K, Zhao Y, Herrera V, Nyirady J, Alexis AF. Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. J Dermatolog Treat. 2017 Dec; 28(8):716-721.
    View in: PubMed
    Score: 0.399
  56. Al Sawah S, Foster SA, Goldblum OM, Malatestinic WN, Zhu B, Shi N, Song X, Feldman SR. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. J Med Econ. 2017 Sep; 20(9):982-990.
    View in: PubMed
    Score: 0.397
  57. Saleem MD, Feldman SR. Comorbidities in patients with psoriasis: The role of the dermatologist. J Am Acad Dermatol. 2017 07; 77(1):191-192.
    View in: PubMed
    Score: 0.397
  58. Shah K, Mellars L, Changolkar A, Feldman SR. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017 Aug; 77(2):287-292.e4.
    View in: PubMed
    Score: 0.395
  59. Saleem MD, Feldman SR. Desoximetasone 0.25% spray, adrenal suppression and efficacy in extensive plaque psoriasis. J Dermatolog Treat. 2018 Feb; 29(1):36-38.
    View in: PubMed
    Score: 0.394
  60. Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018 Feb; 29(1):13-18.
    View in: PubMed
    Score: 0.394
  61. Saleem MD, Negus D, Feldman SR. Topical 0.25% desoximetasone spray efficacy for moderate to severe plaque psoriasis: a randomized clinical trial. J Dermatolog Treat. 2018 Feb; 29(1):32-35.
    View in: PubMed
    Score: 0.394
  62. Feldman SR, Tian H, Gilloteau I, Mollon P, Shu M. Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database. BMC Health Serv Res. 2017 05 08; 17(1):337.
    View in: PubMed
    Score: 0.393
  63. Feldman SR, Zhao Y, Zhou H, Herrera V, Tian H, Li Y. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis. J Manag Care Spec Pharm. 2017 May; 23(5):583-589.
    View in: PubMed
    Score: 0.392
  64. Hawkins SD, Barilla S, Feldman SR. Web app based patient education in psoriasis - a randomized controlled trial. Dermatol Online J. 2017 Apr 15; 23(4).
    View in: PubMed
    Score: 0.391
  65. Amato DA, Malatestinic WN, Palmgren MC, Feldman SR. Dermatologists: Collaborating With Payers to Optimize Coverage Policies. J Drugs Dermatol. 2017 Mar 01; 16(3):228-232.
    View in: PubMed
    Score: 0.387
  66. Hill D, Feldman SR. Cost of diagnosing psoriasis and rosacea for dermatologists versus primary care physicians. Cutis. 2017 Feb; 99(2):134-136.
    View in: PubMed
    Score: 0.385
  67. Smith J, Cline A, Feldman SR. Advances in Psoriasis. South Med J. 2017 01; 110(1):65-75.
    View in: PubMed
    Score: 0.383
  68. Saleem MD, Kesty C, Feldman SR. Relative versus absolute risk of comorbidities in patients with psoriasis. J Am Acad Dermatol. 2017 Mar; 76(3):531-537.
    View in: PubMed
    Score: 0.382
  69. James SM, Hill DE, Feldman SR. Hypothyroidism in Patients with Psoriasis or Rosacea: A Large Population Study. Dermatol Online J. 2016 Oct 15; 22(10).
    View in: PubMed
    Score: 0.378
  70. Faulks SW, Feldman SR. Presenting treatment safety data: subjective interpretations of objective information. Cutis. 2016 Oct; 98(4):259-262.
    View in: PubMed
    Score: 0.377
  71. Feldman SR, Thaçi D, Gooderham M, Augustin M, de la Cruz C, Mallbris L, Buonanno M, Tatulych S, Kaur M, Lan S, Valdez H, Mamolo C. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016 Dec; 75(6):1162-1170.e3.
    View in: PubMed
    Score: 0.376
  72. James SM, Hill DE, Feldman SR. Hypothyroidism in Patients with Psoriasis or Rosacea: A Large Population Study. Dermatol Online J. 2016 Sep 15; 22(9).
    View in: PubMed
    Score: 0.375
  73. Kagha KC, Blauvelt A, Anderson KL, Leonardi CL, Feldman SR. A boxed warning for inadequate psoriasis treatment. Cutis. 2016 Sep; 98(3):206-207.
    View in: PubMed
    Score: 0.374
  74. Bartos S, Hill D, Feldman SR. Review of maintenance of response to psoriasis treatments. J Dermatolog Treat. 2016 Aug; 27(4):293-7.
    View in: PubMed
    Score: 0.372
  75. Feldman SR, Levi E, Pathak P, Kakatkar S, Balkrishnan R. First-Line Fixed-Combination Psoriasis Treatment Is Associated With Lower Healthcare Costs. Skinmed. 2016; 14(4):266-272.
    View in: PubMed
    Score: 0.372
  76. Wehausen B, Hill DE, Feldman SR. Most people with psoriasis or rosacea are not being treated: a large population study. Dermatol Online J. 2016 Jul 15; 22(7).
    View in: PubMed
    Score: 0.371
  77. Anderson KL, Huang KE, Huang WW, Feldman SR. Dermatology Residents are Prescribing Tanning Bed Treatment. Dermatol Online J. 2016 Jul 15; 22(7).
    View in: PubMed
    Score: 0.371
  78. Cline A, Hill D, Lewallen R, Feldman SR. Current status and future prospects for biologic treatments of psoriasis. Expert Rev Clin Immunol. 2016 Dec; 12(12):1273-1287.
    View in: PubMed
    Score: 0.370
  79. Hoffman MB, Hill D, Feldman SR. Current challenges and emerging drug delivery strategies for the treatment of psoriasis. Expert Opin Drug Deliv. 2016 Oct; 13(10):1461-73.
    View in: PubMed
    Score: 0.367
  80. Hill D, Farhangian ME, Feldman SR. Increasing adherence to topical therapy in psoriasis through use of solution medication. Dermatol Online J. 2016 May 15; 22(5).
    View in: PubMed
    Score: 0.367
  81. Kin KC, Hill D, Feldman SR. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. Expert Rev Clin Pharmacol. 2016 Jun; 9(6):789-97.
    View in: PubMed
    Score: 0.367
  82. James SM, Hill DE, Feldman SR. Costs of Common Psoriasis Medications, 2010-2014. J Drugs Dermatol. 2016 Mar; 15(3):305-8.
    View in: PubMed
    Score: 0.362
  83. Rouse NC, Farhangian ME, Wehausen B, Feldman SR. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(6):877-84.
    View in: PubMed
    Score: 0.353
  84. Feldman SR, Bushnell DM, Klekotka PA, Scanlon M, Martin ML, Wade SW, Yang W, Pinto L, Kircik L, Viswanathan HN. Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatolog Treat. 2016; 27(3):224-7.
    View in: PubMed
    Score: 0.352
  85. Feldman SR, Zhao Y, Shi L, Tran MH. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis. J Manag Care Spec Pharm. 2015 Oct; 21(10):874-88.
    View in: PubMed
    Score: 0.351
  86. Vaidya TS, Anderson KL, Feldman SR. Even well-controlled psoriasis patients have unmet treatment needs regardless of disease severity. Dermatol Online J. 2015 Sep 17; 21(9).
    View in: PubMed
    Score: 0.350
  87. Farhangian ME, Feldman SR. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate. Am J Clin Dermatol. 2015 Aug; 16(4):285-294.
    View in: PubMed
    Score: 0.347
  88. Feldman SR. New Frontiers in Psoriasis Treatment. J Drugs Dermatol. 2015 Aug; 14(8):776.
    View in: PubMed
    Score: 0.347
  89. Hess JN, Moustafa FA, Kindley KJ, Huang KE, Feldman SR. Is Safety Psoriasis Patients' Overriding Concern? J Cutan Med Surg. 2015 May-Jun; 19(3):201-2.
    View in: PubMed
    Score: 0.341
  90. Hoffman MB, Farhangian M, Feldman SR. Psoriasis during pregnancy: characteristics and important management recommendations. Expert Rev Clin Immunol. 2015 Jun; 11(6):709-20.
    View in: PubMed
    Score: 0.340
  91. Feldman SR. Inflammatory diseases: Integrating biosimilars into clinical practice. Semin Arthritis Rheum. 2015 Jun; 44(6 Suppl):S16-21.
    View in: PubMed
    Score: 0.340
  92. Anderson KL, Feldman SR. A guide to prescribing home phototherapy for patients with psoriasis: the appropriate patient, the type of unit, the treatment regimen, and the potential obstacles. J Am Acad Dermatol. 2015 May; 72(5):868-78.e1.
    View in: PubMed
    Score: 0.338
  93. Anderson KL, Feldman SR. Reasons for Treatment Changes in Patients With Moderate to Severe Psoriasis. J Cutan Med Surg. 2015 Jul-Aug; 19(4):361-6.
    View in: PubMed
    Score: 0.337
  94. Feldman SR, Zhao Y, Navaratnam P, Friedman HS, Lu J, Tran MH. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015 Mar; 21(3):201-9.
    View in: PubMed
    Score: 0.337
  95. Dothard EH, Sandoval LF, Yentzer BA, Feldman SR. Home ultraviolet light therapy for psoriasis: why patients choose other options. Dermatol Online J. 2014 Dec 13; 21(2).
    View in: PubMed
    Score: 0.332
  96. Sandoval LF, Huang KE, Harrison J, Clark A, Feldman SR. Calcipotriene 0.005%--betamethasone dipropionate 0.064% ointment versus topical suspension in the treatment of plaque psoriasis: a randomized pilot study of patient preference. Cutis. 2014 Dec; 94(6):304-9.
    View in: PubMed
    Score: 0.332
  97. Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J. 2014 Aug 17; 20(8).
    View in: PubMed
    Score: 0.325
  98. Feldman SR. Psoriasis: the new and the old. J Drugs Dermatol. 2014 Aug; 13(8):894.
    View in: PubMed
    Score: 0.324
  99. Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct; 14(5):685-705.
    View in: PubMed
    Score: 0.323
  100. Sandoval LF, Pierce A, Feldman SR. Systemic therapies for psoriasis: an evidence-based update. Am J Clin Dermatol. 2014 Jul; 15(3):165-80.
    View in: PubMed
    Score: 0.322
  101. Davis SA, Lin HC, Yu CH, Balkrishnan R, Feldman SR. Underuse of early follow-up visits: a missed opportunity to improve patients' adherence. J Drugs Dermatol. 2014 Jul; 13(7):833-6.
    View in: PubMed
    Score: 0.322
  102. Moustafa F, Feldman SR. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. Dermatol Online J. 2014 May 16; 20(5):22608.
    View in: PubMed
    Score: 0.319
  103. Chiriac A, Ferariu D, Solovan C, Brzezinski P, Feldman SR. Improvement in severe psoriasis associated with isoniazid treatment. Dermatol Online J. 2014 May 16; 20(5):22617.
    View in: PubMed
    Score: 0.319
  104. Al-Dabagh A, Al-Dabagh R, Davis SA, Taheri A, Lin HC, Balkrishnan R, Feldman SR. Systemic corticosteroids are frequently prescribed for psoriasis. J Cutan Med Surg. 2014 May-Jun; 18(3):195-9.
    View in: PubMed
    Score: 0.318
  105. Mauskopf J, Samuel M, McBride D, Mallya UG, Feldman SR. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. Pharmacoeconomics. 2014 Apr; 32(4):395-409.
    View in: PubMed
    Score: 0.317
  106. Semble AL, Davis SA, Feldman SR. Lack of information in current guidelines regarding systemic corticosteroids in inflammatory diseases. Dermatol Online J. 2014 Mar 17; 20(3).
    View in: PubMed
    Score: 0.316
  107. Semble AL, Davis SA, Feldman SR. Safety and tolerability of tumor necrosis factor-a inhibitors in psoriasis: a narrative review. Am J Clin Dermatol. 2014 Feb; 15(1):37-43.
    View in: PubMed
    Score: 0.313
  108. Sandoval LF, Feldman SR. Are wash outs needed in clinical trials of topical agents? J Dermatolog Treat. 2014 Feb; 25(1):1.
    View in: PubMed
    Score: 0.313
  109. Feldman SR, Winkelman W, Baum E, Preston N. Predicting improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spray. J Drugs Dermatol. 2013 Dec; 12(12):1456-60.
    View in: PubMed
    Score: 0.309
  110. Feldman SR. Disease burden and treatment adherence in psoriasis patients. Cutis. 2013 Nov; 92(5):258-63.
    View in: PubMed
    Score: 0.308
  111. Feldman SR, Levi E, Pathak P, Kakatkar S, Balkrishnan R. Using a single product (calcipotriene/betamethasone topical suspension) vs multiple products to manage body and scalp psoriasis: comparisons in resource utilization and costs. J Med Econ. 2013 Dec; 16(12):1405-13.
    View in: PubMed
    Score: 0.307
  112. Zargari O, Hejazi S, Shahidi-Dadras M, Younespour S, Robati R, Firooz A, Toosi P, Feldman SR. Considerable variation among Iranian dermatologists in the dosing and monitoring of methotrexate for treating psoriasis. Int J Dermatol. 2014 Mar; 53(3):385-9.
    View in: PubMed
    Score: 0.307
  113. Sandoval LF, Huang KE, Feldman SR. Adherence to ustekinumab in psoriasis patients. J Drugs Dermatol. 2013 Oct; 12(10):1090-2.
    View in: PubMed
    Score: 0.306
  114. Mireku K, Huang KE, Narahari S, Davis SA, Feldman SR. Psoriasis treatments by payment type in the US outpatient office setting. J Drugs Dermatol. 2013 Oct; 12(10):1095-7.
    View in: PubMed
    Score: 0.306
  115. Lin HC, Alamdari HS, Huang KE, Gustafson CJ, Davis SA, Balkrishnan R, Feldman SR. Prevalence of psoriasis and rosacea comorbidities in the outpatient setting. J Cutan Med Surg. 2013 Sep-Oct; 17(5):295-8.
    View in: PubMed
    Score: 0.304
  116. Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013 Aug; 14(4):315-26.
    View in: PubMed
    Score: 0.302
  117. Feldman SR. The continued evolution of drugs for psoriasis. J Drugs Dermatol. 2013 Aug; 12(8):850-1.
    View in: PubMed
    Score: 0.302
  118. Akamine KL, Gustafson CJ, Yentzer BA, Edison BL, Green BA, Davis SA, Feldman SR. A double-blind, randomized clinical trial of 20% alpha/poly hydroxy acid cream to reduce scaling of lesions associated with moderate, chronic plaque psoriasis. J Drugs Dermatol. 2013 Aug; 12(8):855-9.
    View in: PubMed
    Score: 0.302
  119. Ahn CS, Awadalla F, Huang KE, Yentzer B, Dabade TS, Feldman SR. Patterns of vitamin D analog use for the treatment of psoriasis. J Drugs Dermatol. 2013 Aug; 12(8):906-10.
    View in: PubMed
    Score: 0.302
  120. Taheri A, Cantrell J, Feldman SR. Tachyphylaxis to topical glucocorticoids; what is the evidence? Dermatol Online J. 2013 Jul 14; 19(7):18954.
    View in: PubMed
    Score: 0.301
  121. Al-Dabagh A, Davis SA, Kinney MA, Huang K, Feldman SR. The effect of folate supplementation on methotrexate efficacy and toxicity in psoriasis patients and folic acid use by dermatologists in the USA. Am J Clin Dermatol. 2013 Jun; 14(3):155-61.
    View in: PubMed
    Score: 0.299
  122. West C, Narahari S, O'Neill J, Davis S, Huynh M, Clark A, Boles A, Feldman SR. Adherence to adalimumab in patients with moderate to severe psoriasis. Dermatol Online J. 2013 May 15; 19(5):18182.
    View in: PubMed
    Score: 0.298
  123. Davis SA, Feldman SR. Combination therapy for psoriasis in the United States. J Drugs Dermatol. 2013 May; 12(5):546-50.
    View in: PubMed
    Score: 0.297
  124. Davis SA, Feldman SR. Using Hawthorne effects to improve adherence in clinical practice: lessons from clinical trials. JAMA Dermatol. 2013 Apr; 149(4):490-1.
    View in: PubMed
    Score: 0.295
  125. Feldman SR, Mills M, Brundage T, Eastman WJ. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. J Drugs Dermatol. 2013 Mar; 12(3):300-6.
    View in: PubMed
    Score: 0.294
  126. Tan X, Balkrishnan R, Feldman SR. Infections associated with the use of tumor necrosis factor-a inhibitors in psoriasis. J Drugs Dermatol. 2013 Mar; 12(3):e41-5.
    View in: PubMed
    Score: 0.294
  127. Tablazon IL, Al-Dabagh A, Davis SA, Feldman SR. Risk of cardiovascular disorders in psoriasis patients: current and future. Am J Clin Dermatol. 2013 Feb; 14(1):1-7.
    View in: PubMed
    Score: 0.292
  128. Gustafson CJ, Watkins C, Hix E, Feldman SR. Combination therapy in psoriasis: an evidence-based review. Am J Clin Dermatol. 2013 Feb; 14(1):9-25.
    View in: PubMed
    Score: 0.292
  129. Shutty BG, West C, Huang KE, Landis E, Dabade T, Browder B, O'Neill J, Kinney MA, Feneran AN, Taylor S, Yentzer B, McCall WV, Fleischer AB, Feldman SR. Sleep disturbances in psoriasis. Dermatol Online J. 2013 Jan 15; 19(1):1.
    View in: PubMed
    Score: 0.291
  130. Alamdari HS, Gustafson CJ, Davis SA, Huang W, Feldman SR. Psoriasis and cardiovascular screening rates in the United States. J Drugs Dermatol. 2013 Jan; 12(1):e14-9.
    View in: PubMed
    Score: 0.290
  131. Feldman SR. Department of Dermatology was blessed with a wonderful psoriasis specialist. Foreword. BioDrugs. 2013 Jan; 27 Suppl 1:1-2.
    View in: PubMed
    Score: 0.290
  132. Mudigonda P, Mudigonda T, Feneran AN, Alamdari HS, Sandoval L, Feldman SR. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatol Online J. 2012 Oct 15; 18(10):1.
    View in: PubMed
    Score: 0.286
  133. Mudigonda T, Dabade TS, West CE, Feldman SR. Therapeutic modalities for localized psoriasis: 308-nm UVB excimer laser versus nontargeted phototherapy. Cutis. 2012 Sep; 90(3):149-54.
    View in: PubMed
    Score: 0.284
  134. Feldman SR, Matheson R, Bruce S, Grande K, Markowitz O, Kempers S, Brundage T, Wyres M. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. Am J Clin Dermatol. 2012 Aug 01; 13(4):261-71.
    View in: PubMed
    Score: 0.282
  135. Feldman SR. Message from the guest editor. J Drugs Dermatol. 2012 Aug; 11(8):906.
    View in: PubMed
    Score: 0.282
  136. Kwatra SG, Dabade TS, Gustafson CJ, Feldman SR. JAK inhibitors in psoriasis: a promising new treatment modality. J Drugs Dermatol. 2012 Aug; 11(8):913-8.
    View in: PubMed
    Score: 0.282
  137. Shutty B, West C, Pellerin M, Feldman S. Apremilast as a treatment for psoriasis. Expert Opin Pharmacother. 2012 Aug; 13(12):1761-70.
    View in: PubMed
    Score: 0.280
  138. Martin SL, McGoey ST, Bebo BF, Feldman SR. Patients' educational needs about topical treatments for psoriasis. J Am Acad Dermatol. 2013 Jun; 68(6):e163-8.
    View in: PubMed
    Score: 0.279
  139. Mudigonda T, Dabade TS, Feldman SR. A review of protocols for 308 nm excimer laser phototherapy in psoriasis. J Drugs Dermatol. 2012 Jan; 11(1):92-7.
    View in: PubMed
    Score: 0.271
  140. Mudigonda T, Dabade TS, Feldman SR. A review of targeted ultraviolet B phototherapy for psoriasis. J Am Acad Dermatol. 2012 Apr; 66(4):664-72.
    View in: PubMed
    Score: 0.267
  141. Smith SF, Feldman SR. Tattoo sites and psoriasis. J Drugs Dermatol. 2011 Oct; 10(10):1199-200.
    View in: PubMed
    Score: 0.266
  142. Ghasri P, Yentzer BA, Dabade TS, Feldman SR. Acitretin for the treatment of psoriasis: an assessment of national trends. J Drugs Dermatol. 2011 Aug; 10(8):873-7.
    View in: PubMed
    Score: 0.263
  143. Haushalter K, Murad EJ, Dabade TS, Rowell R, Pearce DJ, Feldman SR. Efficacy of low-dose acitretin in the treatment of psoriasis. J Dermatolog Treat. 2012 Dec; 23(6):400-3.
    View in: PubMed
    Score: 0.263
  144. Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother. 2011 Sep; 12(13):2041-54.
    View in: PubMed
    Score: 0.262
  145. Searles AD, Lee AD, Feldman SR. Is concomitant use of methotrexate and oral retinoids dangerous? A review of the data regarding this combination. J Am Acad Dermatol. 2011 Apr; 64(4):791-3.
    View in: PubMed
    Score: 0.257
  146. Lapolla W, Yentzer BA, Bagel J, Halvorson CR, Feldman SR. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol. 2011 May; 64(5):936-49.
    View in: PubMed
    Score: 0.257
  147. Persad P, Levender MM, Feldman SR. Commentary: psoriasis patients with a history of malignancy represent an important but overlooked study population. Dermatol Online J. 2011 Feb 15; 17(2):10.
    View in: PubMed
    Score: 0.255
  148. Rajpara AN, O'Neill JL, Nolan BV, Yentzer BA, Feldman SR. Review of home phototherapy. Dermatol Online J. 2010 Dec 15; 16(12):2.
    View in: PubMed
    Score: 0.252
  149. Shah A, O'Neill J, Feldman SR. Treatment of moderate-to-severe psoriasis with alefacept for up to one year: a case series. J Drugs Dermatol. 2010 Dec; 9(12):1491-4.
    View in: PubMed
    Score: 0.251
  150. Feldman SR. Psoralen plus ultraviolet A light phototherapy effectiveness. J Am Acad Dermatol. 2010 Oct; 63(4):718.
    View in: PubMed
    Score: 0.248
  151. Rajpara AN, Feldman SR. Adherence to treatment: still the forgotten variable. Arch Dermatol. 2010 Oct; 146(10):1183-4; author reply 1184.
    View in: PubMed
    Score: 0.248
  152. Feldman SR. Approaching psoriasis differently: patient-physician relationships, patient education and choosing the right topical vehicle. J Drugs Dermatol. 2010 Aug; 9(8):908-11.
    View in: PubMed
    Score: 0.246
  153. Uhlenhake EE, Feldman SR. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. Expert Opin Biol Ther. 2010 Jul; 10(7):1105-12.
    View in: PubMed
    Score: 0.244
  154. Tran B, Feldman SR. Insight into psoriasis management: commercial perspectives for the U.S. psoriasis market. J Dermatolog Treat. 2011 Feb; 22(1):18-26.
    View in: PubMed
    Score: 0.243
  155. Yentzer BA, Feldman SR. Trends in home phototherapy adoption in the US: monetary disincentives are only the tip of the iceberg. J Dermatolog Treat. 2011 Feb; 22(1):27-30.
    View in: PubMed
    Score: 0.243
  156. Feldman SR. Placebo response? Psychosom Med. 2010 Jun; 72(5):505; author reply 505-6.
    View in: PubMed
    Score: 0.242
  157. Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2011 Apr; 22(2):65-74.
    View in: PubMed
    Score: 0.241
  158. Balkrishnan R, Bhosle MJ, Fleischer AB, Feldman SR. Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care? J Dermatolog Treat. 2010 May; 21(3):178-84.
    View in: PubMed
    Score: 0.241
  159. Baer AH, Khanna V, Feldman SR. Literature is lacking in discussion of non-adherence in dermatology. J Dermatolog Treat. 2010 Mar; 21(2):109-10.
    View in: PubMed
    Score: 0.239
  160. Nolan BV, Yentzer BA, Feldman SR. A review of home phototherapy for psoriasis. Dermatol Online J. 2010 Feb 15; 16(2):1.
    View in: PubMed
    Score: 0.238
  161. Uhlenhake EE, Kurkowski D, Feldman SR. Conversations on psoriasis--what patients want and what physicians can provide: a qualitative look at patient and physician expectations. J Dermatolog Treat. 2010 Jan; 21(1):6-12.
    View in: PubMed
    Score: 0.236
  162. Gowda S, Goldblum OM, McCall WV, Feldman SR. Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol. 2010 Jul; 63(1):114-23.
    View in: PubMed
    Score: 0.234
  163. Feldman SR, Koo JY, Johnson LA, Preston NJ. Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis. Cutis. 2009 Oct; 84(4 Suppl):25-32.
    View in: PubMed
    Score: 0.232
  164. Al-Kudwah AJ, Feldman SR. Management of psoriasis. South Med J. 2009 Jun; 102(6):631-6.
    View in: PubMed
    Score: 0.226
  165. Zivkovich AH, Feldman SR. Are ointments better than other vehicles for corticosteroid treatment of psoriasis? J Drugs Dermatol. 2009 Jun; 8(6):570-2.
    View in: PubMed
    Score: 0.226
  166. Yarbrough C, Yentzer BA, Yelverton CB, Feldman SR. Continued use of home narrowband ultraviolet B light phototherapy for psoriasis after completion of a clinical trial. J Am Acad Dermatol. 2009 May; 60(5):877-9.
    View in: PubMed
    Score: 0.225
  167. Yentzer BA, Yelverton CB, Simpson GL, Simpson JF, Hwang W, Balkrishnan R, Feldman SR. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis. Dermatol Online J. 2009 Apr 15; 15(4):1.
    View in: PubMed
    Score: 0.224
  168. Kosari P, Feldman SR. Case report: Fluocinonide-induced perioral dermatitis in a patient with psoriasis. Dermatol Online J. 2009 Mar 15; 15(3):15.
    View in: PubMed
    Score: 0.223
  169. McClain R, Yentzer BA, Feldman SR. Keratolytics for psoriasis: are they necessary? Dermatol Online J. 2009 Jan 15; 15(1):11.
    View in: PubMed
    Score: 0.221
  170. Kulkarni AS, Horn E, Balkrishnan R, Feldman S. Severity levels in psoriasis: a separate 'very severe' category not required. J Dermatolog Treat. 2009; 20(1):48-51.
    View in: PubMed
    Score: 0.220
  171. Yentzer BA, Feldman SR. Tanning beds as an alternative for psoriasis when office-based phototherapy is not accessible. J Dermatolog Treat. 2009; 20(4):238-40.
    View in: PubMed
    Score: 0.220
  172. Alikhan A, Sodhi N, Feldman SR. Equating topical treatment of severe psoriasis to keeping money in a mattress. J Dermatolog Treat. 2009; 20(1):1-2.
    View in: PubMed
    Score: 0.220
  173. Lucas J, Ntuen E, Pearce DJ, Fleischer AB, Feldman SR. Methotrexate: understanding the risk in psoriasis patients. J Dermatolog Treat. 2009; 20(5):311-3.
    View in: PubMed
    Score: 0.220
  174. Sigmon JR, Yentzer BA, Feldman SR. Calcitriol ointment: a review of a topical vitamin D analog for psoriasis. J Dermatolog Treat. 2009; 20(4):208-12.
    View in: PubMed
    Score: 0.220
  175. Feldman SR. Many new options for improving patients' care. J Dermatolog Treat. 2009; 20(4):185.
    View in: PubMed
    Score: 0.220
  176. Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol. 2009; 10(6):397-406.
    View in: PubMed
    Score: 0.220
  177. Strowd LC, Yentzer BA, Fleischer AB, Feldman SR. Increasing use of more potent treatments for psoriasis. J Am Acad Dermatol. 2009 Mar; 60(3):478-81.
    View in: PubMed
    Score: 0.219
  178. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, Menter A, van de Kerkhof PC. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008 Dec; 59(6):1009-16.
    View in: PubMed
    Score: 0.216
  179. Yelverton CB, Yentzer BA, Clark A, Pearce DJ, Balkrishnan R, Camacho FT, Boles A, Fleischer AB, Feldman SR. Home narrowband UV-B phototherapy in combination with low-dose acitretin in patients with moderate to severe psoriasis. Arch Dermatol. 2008 Sep; 144(9):1224-5.
    View in: PubMed
    Score: 0.215
  180. Kaufman ED, Lebwohl MG, Krueger GG, Zimmerman G, Horn EJ, Feldman SR. What the National Psoriasis Foundation means to dermatologists and our patients. Cutis. 2008 Sep; 82(3):181-3.
    View in: PubMed
    Score: 0.215
  181. Yentzer BA, Yelverton CB, Pearce DJ, Camacho FT, Makhzoumi Z, Clark A, Boles A, Fleischer AB, Balkrishnan R, Feldman SR. Adherence to acitretin and home narrowband ultraviolet B phototherapy in patients with psoriasis. J Am Acad Dermatol. 2008 Oct; 59(4):577-81.
    View in: PubMed
    Score: 0.213
  182. Huang W, Cordoro KM, Taylor SL, Feldman SR. To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. J Am Acad Dermatol. 2008 Jun; 58(6):970-7.
    View in: PubMed
    Score: 0.209
  183. Stein KR, Pearce DJ, Feldman SR. Targeted UV therapy in the treatment of psoriasis. J Dermatolog Treat. 2008; 19(3):141-5.
    View in: PubMed
    Score: 0.205
  184. Carr D, Tusa MG, Carroll CL, Pearce DJ, Camacho F, Kaur M, Cook C, Willard J, McCarty A, Fleischer AB, Liu CM, Goffe BS, Feldman SR. Open label trial of alefacept in palmoplantar pustular psoriasis. J Dermatolog Treat. 2008; 19(2):97-100.
    View in: PubMed
    Score: 0.205
  185. Awadalla FC, Balkrishnan R, Feldman SR. The distress of psoriasis doesn't necessarily imply good treatment adherence: a lesson from the treatment of sexually transmitted disease. J Dermatolog Treat. 2008; 19(3):132-3.
    View in: PubMed
    Score: 0.205
  186. Feldman SR, Brown KL, Heald P. 'Coral reef' psoriasis: a marker of resistance to topical treatment. J Dermatolog Treat. 2008; 19(5):257-8.
    View in: PubMed
    Score: 0.205
  187. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008 Jan; 58(1):125-35.
    View in: PubMed
    Score: 0.203
  188. Feldman SR. Effectiveness of clobetasol propionate spray 0.05% added to other stable treatments: add-on therapy in the COBRA trial. Cutis. 2007 Nov; 80(5 Suppl):20-8.
    View in: PubMed
    Score: 0.203
  189. Hick J, Feldman SR. Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments. J Am Acad Dermatol. 2007 Dec; 57(6):972-6.
    View in: PubMed
    Score: 0.201
  190. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol. 2007 Dec; 57(6):1059-68.
    View in: PubMed
    Score: 0.200
  191. Ali SM, Brodell RT, Balkrishnan R, Feldman SR. Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol. 2007 Jul; 143(7):912-5.
    View in: PubMed
    Score: 0.198
  192. Feldman SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol. 2007 Jul; 57(1):81-3.
    View in: PubMed
    Score: 0.196
  193. Feldman SR. Misunderstandings. J Dermatolog Treat. 2007; 18(1):4.
    View in: PubMed
    Score: 0.192
  194. Feldman SR, Gelfand JM, Stein Gold L, Jones SD. The role of topical therapy for patients with extensive psoriasis. Cutis. 2007 Jan; 79(1 Suppl 2):18-31.
    View in: PubMed
    Score: 0.192
  195. Garduno J, Bhosle MJ, Balkrishnan R, Feldman SR. Measures used in specifying psoriasis lesion(s), global disease and quality of life: a systematic review. J Dermatolog Treat. 2007; 18(4):223-42.
    View in: PubMed
    Score: 0.192
  196. Awadalla FC, Yentzer B, Balkrishnan R, Feldman SR. A role for denial in poor adherence to psoriasis treatment. J Dermatolog Treat. 2007; 18(6):324-5.
    View in: PubMed
    Score: 0.192
  197. Yelverton CB, Balkrishnan R, Feldman SR. The utility of a data-logging device for measuring adherence to home phototherapy. Photodermatol Photoimmunol Photomed. 2006 Oct; 22(5):270-2.
    View in: PubMed
    Score: 0.188
  198. Kaur M, Oliver B, Hu J, Feldman SR. Nonlaser UVB-targeted phototherapy treatment of psoriasis. Cutis. 2006 Sep; 78(3):200-3.
    View in: PubMed
    Score: 0.187
  199. Pearce DJ, Klinger S, Ziel KK, Murad EJ, Rowell R, Feldman SR. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Arch Dermatol. 2006 Aug; 142(8):1000-4.
    View in: PubMed
    Score: 0.186
  200. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: are ointments really more potent? J Drugs Dermatol. 2006 Jun; 5(6):527-32.
    View in: PubMed
    Score: 0.184
  201. Simpson JF, Yelverton CB, Balkrishnan R, Fleischer A, Lide W, Feldman SR. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis. Manag Care Interface. 2006 Jun; 19(6):39-43.
    View in: PubMed
    Score: 0.184
  202. Pearce DJ, Stealey KH, Balkrishnan R, Fleischer AB, Feldman SR. Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol. 2006 Apr; 45(4):370-4.
    View in: PubMed
    Score: 0.182
  203. Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother. 2006 Feb; 7(2):157-67.
    View in: PubMed
    Score: 0.180
  204. Yelverton CB, Kulkarni AS, Balkrishnan R, Feldman SR. Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis. Manag Care Interface. 2006 Jan; 19(1):33-6, 39.
    View in: PubMed
    Score: 0.179
  205. Feldman SR. Intermittent dosing of biologics for psoriasis. J Dermatolog Treat. 2006; 17(1):5.
    View in: PubMed
    Score: 0.179
  206. Pearce DJ, Singh S, Balkrishnan R, Kulkarni A, Fleischer AB, Feldman SR. The negative impact of psoriasis on the workplace. J Dermatolog Treat. 2006; 17(1):24-8.
    View in: PubMed
    Score: 0.179
  207. Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat. 2006; 17(1):29-37.
    View in: PubMed
    Score: 0.179
  208. Conley J, Nanton J, Dhawan S, Pearce DJ, Feldman SR. Novel combination regimens: biologics and acitretin for the treatment of psoriasis-- a case series. J Dermatolog Treat. 2006; 17(2):86-9.
    View in: PubMed
    Score: 0.179
  209. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. New treatments for psoriasis: which biologic is best? J Dermatolog Treat. 2006; 17(2):96-107.
    View in: PubMed
    Score: 0.179
  210. Kirkland R, Pearce DJ, Balkrishnan R, Feldman SR. Critical factors determining the potency of topical corticosteroids. J Dermatolog Treat. 2006; 17(3):133-5.
    View in: PubMed
    Score: 0.179
  211. Pearce DJ, Higgins KB, Stealey KH, Balkrishnan R, Crane MM, Camacho F, Fleischer AB, Feldman SR. Adverse events from systemic therapies for psoriasis are common in clinical practice. J Dermatolog Treat. 2006; 17(5):288-93.
    View in: PubMed
    Score: 0.179
  212. Pearce DJ, Lucas J, Wood B, Chen J, Balkrishnan R, Feldman SR. Death from psoriasis: representative US data. J Dermatolog Treat. 2006; 17(5):302-3.
    View in: PubMed
    Score: 0.179
  213. Pearce DJ, Camacho F, Balkrishnan R, Fleischer AB, Feldman SR. Trends in on and off-label calcipotriene use. J Dermatolog Treat. 2006; 17(5):308-13.
    View in: PubMed
    Score: 0.179
  214. Greist HM, Pearce DJ, Blauvelt M, Feldman SR. Resident education: effect of the sixth national psoriasis foundation chief residents' meeting. J Cutan Med Surg. 2006 Jan-Feb; 10(1):16-20.
    View in: PubMed
    Score: 0.179
  215. Simpson GL, Yelverton CB, Rittenberg S, Feldman SR. Do utilization management controls for phototherapy increase the prescription of biologics? J Dermatolog Treat. 2006; 17(6):359-61.
    View in: PubMed
    Score: 0.179
  216. McGowan JW, Pearce DJ, Chen J, Richmond D, Balkrishnan R, Feldman SR. The skinny on psoriasis and obesity. Arch Dermatol. 2005 Dec; 141(12):1601-2.
    View in: PubMed
    Score: 0.178
  217. Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol. 2005 Nov; 53(5):887-9.
    View in: PubMed
    Score: 0.177
  218. Balkrishnan R, Camacho FT, Pearce DJ, Kulkarni AS, Spencer L, Fleischer AB, Feldman SR. Factors affecting prescription of ultra-high potency topical corticosteroids in skin disease: an analysis of US national practice data. J Drugs Dermatol. 2005 Nov-Dec; 4(6):699-706.
    View in: PubMed
    Score: 0.177
  219. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Inpatient management of severe psoriasis. J Drugs Dermatol. 2005 Sep-Oct; 4(5):564-70.
    View in: PubMed
    Score: 0.175
  220. Feldman SR, Lucas J, Pearce DJ. A reappraisal of the concept of suppressive versus remittive psoriasis treatments. J Dermatolog Treat. 2005 Aug; 16(3):171-4.
    View in: PubMed
    Score: 0.174
  221. Hancox JG, Balkrishnan R, Battle J, Housman TS, Fleischer AB, Feldman SR. Limited availability of psoriasis and phototherapy care: an analysis of advertisements. Dermatol Online J. 2005 Aug 01; 11(2):6.
    View in: PubMed
    Score: 0.174
  222. Pearce DJ, Boles A, Greist HM, Feldman SR. Biologic therapy for psoriasis: telephone triage. Dermatol Nurs. 2005 Aug; 17(4):265-70, 295.
    View in: PubMed
    Score: 0.174
  223. Feldman SR, Koo JY, Menter A, Bagel J. Decision points for the initiation of systemic treatment for psoriasis. J Am Acad Dermatol. 2005 Jul; 53(1):101-7.
    View in: PubMed
    Score: 0.173
  224. Feldman S, Behnam SM, Behnam SE, Koo JY. Involving the patient: impact of inflammatory skin disease and patient-focused care. J Am Acad Dermatol. 2005 Jul; 53(1 Suppl 1):S78-85.
    View in: PubMed
    Score: 0.173
  225. Feldman SR. Where has Goeckerman treatment gone? J Dermatolog Treat. 2005 Apr; 16(2):73-4.
    View in: PubMed
    Score: 0.170
  226. Dhawan SS, Blyumin ML, Pearce DJ, Feldman SR. Tazarotene cream (0.1%) in combination with betamethasone valerate foam (0.12%) for plaque-type psoriasis. J Drugs Dermatol. 2005 Mar-Apr; 4(2):228-30.
    View in: PubMed
    Score: 0.169
  227. Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005 Mar; 24(1):52-7.
    View in: PubMed
    Score: 0.169
  228. Kulkarni AS, Balkrishnan R, Richmond D, Pearce DJ, Feldman SR. Medication-related factors affecting health care outcomes and costs for patients with psoriasis in the United States. J Am Acad Dermatol. 2005 Jan; 52(1):27-31.
    View in: PubMed
    Score: 0.167
  229. Feldman SR, Nijsten T, Margolis DJ, Rolstad T. Systemic therapy does not usually clear psoriasis, but treatment success does not require clearing. J Am Acad Dermatol. 2005 Jan; 52(1):140-1.
    View in: PubMed
    Score: 0.167
  230. Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol. 2005 Jan; 141(1):43-6.
    View in: PubMed
    Score: 0.167
  231. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Infliximab for inpatient psoriasis management--is there a role? J Dermatolog Treat. 2005; 16(5-6):314-8.
    View in: PubMed
    Score: 0.167
  232. Pearce DJ, Morrison AE, Higgins KB, Crane MM, Balkrishnan R, Fleischer AB, Feldman SR. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat. 2005; 16(5-6):319-23.
    View in: PubMed
    Score: 0.167
  233. Su J, Pearce DJ, Feldman SR. The role of commercial tanning beds and ultraviolet A light in the treatment of psoriasis. J Dermatolog Treat. 2005; 16(5-6):324-6.
    View in: PubMed
    Score: 0.167
  234. Kulkarni AS, Balkrishnan R, Camacho FT, Anderson RT, Feldman SR. Medication and health care service utilization related to depressive symptoms in older adults with psoriasis. J Drugs Dermatol. 2004 Nov-Dec; 3(6):661-6.
    View in: PubMed
    Score: 0.165
  235. Hu J, Balkrishnan R, Camacho F, Lang W, Pearce DJ, Fleischer AB, Feldman SR. The frequent use of oral retinoids in combination with other treatments for psoriasis: a retrospective analysis. J Cutan Med Surg. 2004 Nov-Dec; 8(6):411-4.
    View in: PubMed
    Score: 0.165
  236. Louden BA, Pearce DJ, Lang W, Feldman SR. A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. Dermatol Online J. 2004 Oct 15; 10(2):7.
    View in: PubMed
    Score: 0.164
  237. Pearce DJ, Thomas CG, Fleischer AB, Feldman SR. The cost of psoriasis therapies: considerations for therapy selection. Dermatol Nurs. 2004 Oct; 16(5):421-8, 432.
    View in: PubMed
    Score: 0.164
  238. Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004 Mar; 50(3):416-30.
    View in: PubMed
    Score: 0.157
  239. Rapp SR, Feldman SR. The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life? Dermatol Ther. 2004; 17(5):376-82.
    View in: PubMed
    Score: 0.156
  240. Feldman S. Modest innovations in psoriasis treatment? J Dermatolog Treat. 2003 Dec; 14(4):198-9.
    View in: PubMed
    Score: 0.155
  241. Feldman SR, Garton R, Averett W, Balkrishnan R, Vallee J. Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother. 2003 Sep; 4(9):1525-33.
    View in: PubMed
    Score: 0.152
  242. Pettey AA, Balkrishnan R, Rapp SR, Fleischer AB, Feldman SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 2003 Aug; 49(2):271-5.
    View in: PubMed
    Score: 0.151
  243. Feldman SR. The design of clinical trials in psoriasis: lessons for clinical practice. J Am Acad Dermatol. 2003 Aug; 49(2 Suppl):S62-5.
    View in: PubMed
    Score: 0.151
  244. Housman TS, Keil KA, Mellen BG, McCarty MA, Fleischer AB, Feldman SR. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol. 2003 Jul; 49(1):79-82.
    View in: PubMed
    Score: 0.150
  245. Wilson JK, Al-Suwaidan SN, Krowchuk D, Feldman SR. Treatment of psoriasis in children: is there a role for antibiotic therapy and tonsillectomy? Pediatr Dermatol. 2003 Jan-Feb; 20(1):11-5.
    View in: PubMed
    Score: 0.145
  246. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003; 4(4):221-4.
    View in: PubMed
    Score: 0.145
  247. Lebwohl M, Menter A, Koo J, Feldman S. Case studies in severe psoriasis: A clinical strategy. J Dermatolog Treat. 2003; 14 Suppl 2:26-46.
    View in: PubMed
    Score: 0.145
  248. Housman TS, Mellen BG, Rapp SR, Fleischer AB, Feldman SR. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002 Dec; 70(6):327-32.
    View in: PubMed
    Score: 0.144
  249. Tauscher AE, Fleischer AB, Phelps KC, Feldman SR. Psoriasis and pregnancy. J Cutan Med Surg. 2002 Nov-Dec; 6(6):561-70.
    View in: PubMed
    Score: 0.143
  250. Feldman SR. Remissions of psoriasis with excimer laser treatment. J Drugs Dermatol. 2002 Jul; 1(1):13-4.
    View in: PubMed
    Score: 0.140
  251. Feldman SR, Mellen BG, Housman TS, Fitzpatrick RE, Geronemus RG, Friedman PM, Vasily DB, Morison WL. Efficacy of the 308-nm excimer laser for treatment of psoriasis: results of a multicenter study. J Am Acad Dermatol. 2002 Jun; 46(6):900-6.
    View in: PubMed
    Score: 0.139
  252. Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, Feldman SR. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol. 2002 May; 41(5):269-74.
    View in: PubMed
    Score: 0.139
  253. Housman TS, Rohrback JM, Fleischer AB, Feldman SR. Phototherapy utilization for psoriasis is declining in the United States. J Am Acad Dermatol. 2002 Apr; 46(4):557-9.
    View in: PubMed
    Score: 0.138
  254. Rodewald EJ, Housman TS, Mellen BG, Feldman SR. Follow-up survey of 308-nm laser treatment of psoriasis. Lasers Surg Med. 2002; 31(3):202-6.
    View in: PubMed
    Score: 0.135
  255. Chan AA, Noguti J, Yang CT, Feldman SR, Wallace RB, Shadyab AH, Manson JE, Aragaki AK, Chlebowski RT, Lee DJ. Association between menopausal hormone therapy and incidence of psoriasis: a secondary analysis from the Women's Health Initiative randomized clinical trials. Br J Dermatol. 2021 09; 185(3):669-671.
    View in: PubMed
    Score: 0.130
  256. Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Gondo G, Heydon S, Koons S, Ritchlin CT. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021 05; 84(5):1254-1268.
    View in: PubMed
    Score: 0.127
  257. Gao JC, Emmerich VK, Feldman S, Strowd LC. Evaluating calcipotriene 0.005% foam for the treatment of plaque psoriasis of the scalp and body in patients aged 12 years and older. Expert Opin Pharmacother. 2021 Apr; 22(5):543-547.
    View in: PubMed
    Score: 0.126
  258. Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Choon SE, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Di Meglio P, Langan SM, Capon F, Griffiths CEM, Barker JN, Smith CH. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021 01; 147(1):60-71.
    View in: PubMed
    Score: 0.125
  259. Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CT. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. J Am Acad Dermatol. 2020 Dec; 83(6):1704-1716.
    View in: PubMed
    Score: 0.124
  260. Egeberg A, Girolomoni G, Feldman SR, Radtke MA, Carrascosa JM, Ghil J, Keum JW, Lee J, Seo H. Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Drugs Dermatol. 2020 Mar 01; 19(3):316-318.
    View in: PubMed
    Score: 0.119
  261. Nadkarni A, Hyde K, Cardwell LA, Feldman SR. Biologics monitoring: incongruity between recommendations and clinician monitoring trends. J Dermatolog Treat. 2020 Aug; 31(5):450-451.
    View in: PubMed
    Score: 0.118
  262. Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020 Feb; 29(2):369-380.
    View in: PubMed
    Score: 0.116
  263. Jackson DG, Cardwell LA, Oussedik E, Feldman SR. Utility of boron in dermatology. J Dermatolog Treat. 2020 Feb; 31(1):2-12.
    View in: PubMed
    Score: 0.116
  264. Bray JK, Johnson MC, Masicampo EJ, Feldman SR. Optimizing presentation of expected treatment outcomes. J Am Acad Dermatol. 2020 Aug; 83(2):602-604.
    View in: PubMed
    Score: 0.114
  265. Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF. A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2019 Jul; 81(1):102-110.
    View in: PubMed
    Score: 0.112
  266. Guda A, Feldman SR, Strowd L. Investigational drugs in phase II clinical trials for moderate to severe plaque psoriasis - potential new treatments on the horizon. Expert Opin Investig Drugs. 2018 11; 27(11):931-939.
    View in: PubMed
    Score: 0.108
  267. Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat. 2018 Dec; 29(8):769-774.
    View in: PubMed
    Score: 0.105
  268. Gionfriddo MR, Pulk RA, Sahni DR, Vijayanagar SG, Chronowski JJ, Jones LK, Evans MA, Feldman SR, Pride H. ProvenCare-Psoriasis: A disease management model to optimize care. Dermatol Online J. 2018 03 15; 24(3).
    View in: PubMed
    Score: 0.104
  269. Rajabi-Estarabadi A, Hasanzadeh H, Taheri A, Feldman SR, Firooz A. The efficacy of short-term clobetasol lotion in the treatment of scalp psoriasis. J Dermatolog Treat. 2018 Mar; 29(2):111-115.
    View in: PubMed
    Score: 0.099
  270. Asche CV, Kim M, Feldman SR, Zografos P, Lu M. Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs. J Med Econ. 2017 Sep; 20(9):1000-1006.
    View in: PubMed
    Score: 0.099
  271. Papp KA, Bissonnette R, Gooderham M, Feldman SR, Iversen L, Soung J, Draelos Z, Mamolo C, Purohit V, Wang C, Ports WC. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. BMC Dermatol. 2016 10 03; 16(1):15.
    View in: PubMed
    Score: 0.094
  272. Armstrong AW, Feldman SR, Korman NJ, Meng X, Guana A, Nyirady J, Herrera V, Zhao Y. Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017 May; 28(3):200-205.
    View in: PubMed
    Score: 0.093
  273. Clowse ME, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB, Xibillé D, Chen Y, Frazier D, Geier J, Proulx J, Marren A. Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Saf. 2016 08; 39(8):755-62.
    View in: PubMed
    Score: 0.093
  274. Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016 May; 74(5):841-50.
    View in: PubMed
    Score: 0.090
  275. Mathias SD, Feldman SR, Crosby RD, Colwell HH, McQuarrie K, Han C. Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary. J Dermatolog Treat. 2016 Aug; 27(4):322-7.
    View in: PubMed
    Score: 0.089
  276. Ports WC, Feldman SR, Gupta P, Tan H, Johnson TR, Bissonnette R. Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design. J Drugs Dermatol. 2015 Aug; 14(8):777-84.
    View in: PubMed
    Score: 0.087
  277. Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW. To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2015 Sep; 73(3):420-8.e1.
    View in: PubMed
    Score: 0.087
  278. Shaw MK, Davis SA, Feldman SR, Fleischer AB. Trends in systemic psoriasis treatment therapies from 1993 through 2010. J Drugs Dermatol. 2014 Aug; 13(8):917-20.
    View in: PubMed
    Score: 0.081
  279. Cresce ND, Davis SA, Huang WW, Feldman SR. The quality of life impact of acne and rosacea compared to other major medical conditions. J Drugs Dermatol. 2014 Jun; 13(6):692-7.
    View in: PubMed
    Score: 0.080
  280. Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015 Feb; 26(1):23-31.
    View in: PubMed
    Score: 0.078
  281. Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, Gottlieb AB, Koo JY, Lebwohl M, Leonardi CL, Van Voorhees AS, Bhushan R, Menter A. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. 2014 Jan; 70(1):146-67.
    View in: PubMed
    Score: 0.077
  282. Davis SA, Yentzer BA, Feldman SR. Acitretin prescribing patterns in women of childbearing potential. J Drugs Dermatol. 2013 Jul 01; 12(7):799-802.
    View in: PubMed
    Score: 0.075
  283. Kim IH, West CE, Kwatra SG, Feldman SR, O'Neill JL. Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol. 2012 Dec 01; 13(6):365-74.
    View in: PubMed
    Score: 0.072
  284. Wong JW, Davis SA, Feldman SR, Koo JY. Trends in older adult psoriasis outpatient health care practices in the United States. J Drugs Dermatol. 2012 Aug; 11(8):957-62.
    View in: PubMed
    Score: 0.071
  285. Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012 Jan; 148(1):95-102.
    View in: PubMed
    Score: 0.068
  286. Vogel SA, Yentzer B, Davis SA, Feldman SR, Cordoro KM. Trends in pediatric psoriasis outpatient health care delivery in the United States. Arch Dermatol. 2012 Jan; 148(1):66-71.
    View in: PubMed
    Score: 0.066
  287. Kaminska E, Patel I, Dabade TS, Chang J, Qureshi AA, O'Neill JL, Balkrishnan R, Feldman SR. Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmarks of risk. J Dermatolog Treat. 2013 Apr; 24(2):101-6.
    View in: PubMed
    Score: 0.066
  288. Dunn LK, Gaar LR, Yentzer BA, O'Neill JL, Feldman SR. Acitretin in dermatology: a review. J Drugs Dermatol. 2011 Jul; 10(7):772-82.
    View in: PubMed
    Score: 0.065
  289. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL, Lim HW, Van Voorhees AS, Beutner KR, Ryan C, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul; 65(1):137-74.
    View in: PubMed
    Score: 0.064
  290. Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatolog Treat. 2011 Jun; 22(3):138-43.
    View in: PubMed
    Score: 0.063
  291. Lin HC, Lucas PT, Feldman SR, Balkrishnan R. Medication use and associated health care outcomes and costs for patients with psoriasis in the United States. J Dermatolog Treat. 2012 Jun; 23(3):196-202.
    View in: PubMed
    Score: 0.063
  292. Zeichner JA, Lebwohl MG, Menter A, Bagel J, Del Rosso JQ, Elewski BE, Feldman SR, Kircik LH, Koo J, Gold LS, Tanghetti E. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis. 2010 Sep; 86(3 Suppl):5-31; quiz 32.
    View in: PubMed
    Score: 0.062
  293. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep; 63(3):457-65.
    View in: PubMed
    Score: 0.060
  294. Iaconi A, Feldman SR, Balkrishnan R. Psoriasis and its treatment with adalimumab. Expert Opin Biol Ther. 2010 Jan; 10(1):133-52.
    View in: PubMed
    Score: 0.059
  295. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JYM, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010 Jan; 62(1):114-135.
    View in: PubMed
    Score: 0.058
  296. Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009; 219(3):209-18.
    View in: PubMed
    Score: 0.057
  297. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009 Apr; 60(4):643-59.
    View in: PubMed
    Score: 0.055
  298. Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK. Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Curr Med Res Opin. 2008 Dec; 24(12):3493-501.
    View in: PubMed
    Score: 0.055
  299. Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes. 2008 Oct 02; 6:75.
    View in: PubMed
    Score: 0.054
  300. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May; 58(5):826-50.
    View in: PubMed
    Score: 0.053
  301. Sumner W, Feldman SR. Conversion to positive tuberculosis test during etanercept treatment of psoriasis. J Drugs Dermatol. 2007 Oct; 6(10):1048.
    View in: PubMed
    Score: 0.050
  302. Price J, Bhosle M, Feldman SR, Balkrishnan R. Outcomes associated with the use of biologic agents in moderate to severe psoriasis. J Drugs Dermatol. 2007 Mar; 6(3):259-67.
    View in: PubMed
    Score: 0.048
  303. Steele T, Pawaskar M, Balkrishnan R, Fleischer A, Feldman SR. Does cost-effectiveness play a role in clinical trials? Dermatol Ther. 2007 Mar-Apr; 20(2):110-9.
    View in: PubMed
    Score: 0.048
  304. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007 Jan; 56(1):31.e1-15.
    View in: PubMed
    Score: 0.047
  305. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006 Jun 06; 4:35.
    View in: PubMed
    Score: 0.046
  306. Bhosle MJ, Feldman SR, Camacho FT, Timothy Whitmire J, Nahata MC, Balkrishnan R. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat. 2006; 17(5):294-301.
    View in: PubMed
    Score: 0.045
  307. Lebwohl M, Freeman A, Chapman MS, Feldman S, Hartle J, Henning A. Proven efficacy of tacrolimus for facial and intertriginous psoriasis. Arch Dermatol. 2005 Sep; 141(9):1154.
    View in: PubMed
    Score: 0.044
  308. Lowe N, Feldman SR, Sherer D, Weiss J, Shavin JS, Lin YL, Foley V, Soto P. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. J Dermatolog Treat. 2005 Aug; 16(3):158-64.
    View in: PubMed
    Score: 0.043
  309. Marchetti A, Feldman SR, Kimball AB, Anderson RR, Miller LH, Martin J, An P. Treatments for mild-to-moderate recalcitrant plaque psoriasis: expected clinical and economic outcomes for first-line and second-line care. Dermatol Online J. 2005 Mar 01; 11(1):1.
    View in: PubMed
    Score: 0.042
  310. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005 Mar; 52(3 Pt 1):425-33.
    View in: PubMed
    Score: 0.042
  311. Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol. 2005 Mar; 52(3 Pt 1):434-44.
    View in: PubMed
    Score: 0.042
  312. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, Margolis DJ. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005 Jan; 52(1):23-6.
    View in: PubMed
    Score: 0.042
  313. Nijsten T, Rolstad T, Feldman SR, Stern RS. Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol. 2005 Jan; 141(1):19-26.
    View in: PubMed
    Score: 0.042
  314. Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005 Jan; 141(1):82-4.
    View in: PubMed
    Score: 0.042
  315. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004 Nov; 51(5):704-8.
    View in: PubMed
    Score: 0.041
  316. Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004 Nov; 51(5):723-30.
    View in: PubMed
    Score: 0.041
  317. Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004 Aug; 51(2):212-6.
    View in: PubMed
    Score: 0.041
  318. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004 Jun; 50(6):859-66.
    View in: PubMed
    Score: 0.040
  319. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004 Mar; 9(2):136-9.
    View in: PubMed
    Score: 0.039
  320. Menter MA, Krueger GC, Feldman SR, Weinstein GD. Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. J Am Acad Dermatol. 2003 Aug; 49(2 Suppl):S39-43.
    View in: PubMed
    Score: 0.038
  321. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J. 2003 Feb; 9(1):2.
    View in: PubMed
    Score: 0.037
  322. Wilson JK, Phelps KC, Feldman SR. Use of transcutaneous nerve stimulation wristband to treat methotrexate-induced nausea. J Cutan Med Surg. 2002 Nov-Dec; 6(6):551-3.
    View in: PubMed
    Score: 0.036
  323. Tan X, Feldman SR, Chang J, Balkrishnan R. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv. 2012 Oct; 9(10):1263-71.
    View in: PubMed
    Score: 0.018
  324. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009 Sep; 61(3):451-85.
    View in: PubMed
    Score: 0.014
  325. Hundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR, Jorizzo JL. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol. 2006 Feb; 54(2):217-20.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.